Correction to: Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Works matching IS 01145916 AND DT 2020 AND VI 43 AND IP 8
Results: 15
1
2
Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 691, doi. 10.1007/s40264-020-00976-7
- By:
- Publication type:
- Article
3
Correction to: Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
4
Correction to: Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
5
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 767, doi. 10.1007/s40264-020-00936-1
- By:
- Publication type:
- Article
6
Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 751, doi. 10.1007/s40264-020-00934-3
- By:
- Publication type:
- Article
7
Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 745, doi. 10.1007/s40264-020-00932-5
- By:
- Publication type:
- Article
8
Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 727, doi. 10.1007/s40264-020-00931-6
- By:
- Publication type:
- Article
9
Oxycodone, Hydromorphone, and the Risk of Suicide: A Retrospective Population-Based Case–Control Study.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 737, doi. 10.1007/s40264-020-00924-5
- By:
- Publication type:
- Article
10
Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 809, doi. 10.1007/s40264-020-00966-9
- By:
- Publication type:
- Article
11
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 699, doi. 10.1007/s40264-020-00965-w
- By:
- Publication type:
- Article
12
Prospective Evaluation of Adverse Event Recognition Systems in Twitter: Results from the Web-RADR Project.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 797, doi. 10.1007/s40264-020-00942-3
- By:
- Publication type:
- Article
13
Detecting Medicine Safety Signals Using Prescription Sequence Symmetry Analysis of a National Prescribing Data Set.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 787, doi. 10.1007/s40264-020-00940-5
- By:
- Publication type:
- Article
14
A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 775, doi. 10.1007/s40264-020-00939-y
- By:
- Publication type:
- Article
15
Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
- Published in:
- Drug Safety, 2020, v. 43, n. 8, p. 711, doi. 10.1007/s40264-020-00938-z
- By:
- Publication type:
- Article